source
- Setara Biosciences launches with $90 million to pursue Charcot-Marie-Tooth and other rare-disease therapiesSetara Biosciences announced its formation on Friday, backed by $90 million of financing to advance a pipeline of experimental medicines. The company’s first candidate targets the genetic disorder…
- Aspen Neuroscience and Bambusa raise $310M combined in IPOsAspen Neuroscience, a biotech focused on cell therapy for Parkinson's disease, announced it will raise about $141 million through its initial public offering scheduled for Friday. Bambusa, a start…